Mezzion Pharma Co.Ltd

Mezzion Pharma Co., Ltd. develops, licenses, and commercializes drugs for vascular diseases. Its lead candidate is Udenafil, a PDE5 inhibitor being developed for erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary disease. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co., Ltd. in April 2013. Founded in 2002, it is based in Seoul, South Korea.